P1617: A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A PEGYLATED-RECOMBINANT HUMAN COAGULATION FACTOR VIII-FC FUSION PROTEIN WITH HALF-LIFE IN PATIENTS WITH SEVERE HEMOPHILIA A

• Feng Xue,
• Yun Chen Chen,
• Jing Sun,
• Shuxia Guo,
• Qing Wen,
• Chongyuan Xu,
• Renchi Yang

Affiliations

Feng Xue

1 Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Blood Diseases, Tianjin, China

Yun Chen Chen

2 Jinan central hospita, Department of Hematology, Jinan, China

Jing Sun

3 Nanfang Hospital of Southern Medical University, Department of Hematology, Guangzhou, China

Shuxia Guo

4 Zhengzhou People’s Hospital, Department of Hematology, Zhengzhou, China

Qing Wen

5 Jinan central hospita, Office of Drug Clinical Trial Institutions, Jinan, China

Chongyuan Xu

6 Nanfang Hospital of Southern Medical University, Office of Drug Clinical Trial Institutions, Guangzhou, China

Renchi Yang

7 Chinese Academy of Medical Sciences & Peking Union Medical College, Thrombosis And Hemostasis Diagnosis And Treatment Center, Tianjin, China